Patients with any other primary DSM-IV psychiatric diagnosis in addition to Obsessive Compulsive Disorder.
Patients who currently fulfil criteria for DSM-IV eating disorder, body dysmorphic disorder, current alcohol or substance abuse, or who have a lifetime history of bipolar disorder. Patients with a history of Schizophrenia and other psychotic disorders, Delirium, Dementia, and Amnestic and other cognitive disorders.
Subjects with a concurrent Axis II Cluster A Personality Disorder
Borderline or Antisocial Personality Disorder.
Subjects who based on history or mental status examination have a significant risk of committing suicide, in the investigator's opinion.
Subjects with a history of more than three adequate trials with an SSRI.
Subjects who have had an adequate trial of pregabalin.
Subjects who have initiated psychotherapy in the last 4 months prior to the first visit.
Subjects who, during the course of the study, would be likely to require treatment with prohibited concomitant therapy .
Prior use of or a known allergy or hypersensitivity to pregabalin.
Subjects who have participated in any clinical trial within 30 days prior to entering the study, or in a clinical trial involving a psychotropic medication within the 6 months prior to entering the study.
Any subject who has been taking benzodiazepines before entering the study who: 1) cannot tolerate being free of benzodiazepines for 4 weeks, or 2) has signs or symptoms of benzodiazepine withdrawal or rebound at the end of those 4 weeks. Should a patient entering the study, who is currently on benzodiazepines develop discontinuation symptoms with discontinuation of their benzodiazepine, we will treat these symptoms with a more gradual benzodiazepine taper. Study will be delayed until the patient is able to tolerate the discontinuation for 4 weeks.
Patients with a current seizure disorder, organic brain disorder or a history of seizure disorders (except for febrile seizures in childhood).
Patients with thyroid pathology, the treatment of which has not been stabilized for at least three months.
Patients on neuroleptic drugs in the two months prior to study entry or cognitive behavioural therapy specific to OCD within four weeks of study entry
Pregnant or lactating females, or if sexually active and of childbearing potential, not using adequate methods of birth control.
Patients with a history or evidence of a medical condition that would expose them to an increased risk of a significant adverse event or interfere with assessments of safety and efficacy during the trial.
Patients receiving psychotropics of any kind, including betablockers and other anticonvulsants. Sleep medication such as oral chloral-hydrate or zopiclone are acceptable.
Patients using any herbal psychoactive treatments, e.g. St John's Wort, Valerian, Kava Kava, L-tryptophan.
Patients with any condition or on any therapy that, in the investigator's opinion, or as indicated in the pregabalin product label, may pose a risk to the subject.
Patients who have had a major life event in the past three months, which in the judgement of the investigator is influencing their current condition.
Patients having clinically significant abnormal laboratory, or ECG findings not resolved by further examinations.

NCT00994786_exc_T1
Qualifier
any other
NCT00994786_exc_T2
Negation
in addition to
NCT00994786_exc_T3
Condition
Obsessive Compulsive Disorder
NCT00994786_exc_T4
Condition
psychiatric diagnosis
NCT00994786_exc_T5
Qualifier
primary
NCT00994786_exc_T6
Qualifier
DSM-IV
NCT00994786_exc_T7
Scope
any other primary DSM-IV
NCT00994786_exc_T8
Condition
eating disorder
NCT00994786_exc_T9
Condition
body dysmorphic disorder
NCT00994786_exc_T10
Condition
substance abuse
NCT00994786_exc_T11
Condition
lcohol buse,
NCT00994786_exc_T12
Condition
bipolar disorder
NCT00994786_exc_T13
Condition
Schizophrenia
NCT00994786_exc_T14
Condition
psychotic disorders
NCT00994786_exc_T15
Qualifier
other
NCT00994786_exc_T16
Condition
Delirium
NCT00994786_exc_T17
Condition
Dementia
NCT00994786_exc_T18
Condition
Amnestic
NCT00994786_exc_T19
Condition
cognitive disorders
NCT00994786_exc_T20
Qualifier
other
NCT00994786_exc_T21
Qualifier
DSM-IV
NCT00994786_exc_T22
Scope
eating disorder, body dysmorphic disorder, current alcohol or substance abuse
NCT00994786_exc_T23
Condition
Personality Disorder
NCT00994786_exc_T24
Qualifier
Axis II Cluster A
NCT00994786_exc_T25
Condition
Antisocial Personality Disorder
NCT00994786_exc_T26
Condition
derline or sonality Disorder.
S
NCT00994786_exc_T27
Procedure
mental status examination
NCT00994786_exc_T28
Observation
risk of committing suicide
NCT00994786_exc_T29
Qualifier
significant
NCT00994786_exc_T33
Procedure
psychotherapy
NCT00994786_exc_T34
Temporal
in the last 4 months prior to the first visit
NCT00994786_exc_T35
Reference_point
first visit
NCT00994786_exc_T37
Condition
allergy
NCT00994786_exc_T38
Condition
hypersensitivity
NCT00994786_exc_T39
Drug
pregabalin
NCT00994786_exc_T40
Scope
allergy or hypersensitivity
NCT00994786_exc_T43
Condition
seizure disorder
NCT00994786_exc_T44
Condition
organic brain disorder
NCT00994786_exc_T45
Condition
history of seizure disorders
NCT00994786_exc_T46
Negation
except
NCT00994786_exc_T47
Condition
febrile seizures
NCT00994786_exc_T48
Qualifier
childhood
NCT00994786_exc_T49
Condition
thyroid pathology
NCT00994786_exc_T50
Temporal
at least three months
NCT00994786_exc_T51
Negation
not
NCT00994786_exc_T52
Qualifier
stabilized
NCT00994786_exc_T53
Procedure
treatment
NCT00994786_exc_T54
Drug
neuroleptic drugs
NCT00994786_exc_T55
Temporal
in the two months prior to study entry
NCT00994786_exc_T56
Reference_point
study entry
NCT00994786_exc_T57
Procedure
cognitive behavioural therapy
NCT00994786_exc_T58
Condition
OCD
NCT00994786_exc_T59
Temporal
within four weeks of study entry
NCT00994786_exc_T60
Reference_point
study entry
NCT00994786_exc_T63
Drug
psychotropics
NCT00994786_exc_T64
Drug
betablockers
NCT00994786_exc_T65
Drug
anticonvulsants
NCT00994786_exc_T66
Scope
betablockers and other anticonvulsants
NCT00994786_exc_T67
Drug
Sleep medication
NCT00994786_exc_T68
Negation
acceptable
NCT00994786_exc_T69
Drug
zopiclone
NCT00994786_exc_T70
Drug
chloral-hydrate
NCT00994786_exc_T71
Qualifier
oral
NCT00994786_exc_T72
Scope
oral chloral-hydrate or zopiclone
NCT00994786_exc_T73
Procedure
herbal psychoactive treatments
NCT00994786_exc_T74
Drug
St John's Wort
NCT00994786_exc_T75
Drug
Valerian
NCT00994786_exc_T76
Drug
Kava Kava
NCT00994786_exc_T77
Drug
L-tryptophan
NCT00994786_exc_T78
Scope
St John's Wort, Valerian, Kava Kava, L-tryptophan
NCT00994786_exc_T81
Measurement
ndings not  by fur
NCT00994786_exc_T82
Measurement
ECG findings
NCT00994786_exc_T83
Value
significant abnormal
NCT00994786_exc_T84
Scope
laboratory, or ECG findings